ESSA’s primary research efforts are focused on developing small molecule therapies to treat patients with androgen receptor (AR)-driven prostate cancer, with a focus on new treatment modalities targeting the N-terminal domain (NTD) of the AR. Our lead candidate, EPI-7386, is a first-in-class NTD AR inhibitor (Aniten) that suppresses androgen biology through a novel mechanism of action. ESSA’s highly differentiated approach has the potential to bypass current AR-based resistance mechanisms that develop in patients with castration-resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCRPC).

ESSA is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology. In preclinical models, ANITAC degraders eliminate forms of AR protein that can potentially drive disease progression in CRPC and mCRPC.